PRISM BioLab Co

PRISM BioLab Co Net Margin

The Net Profit Margin of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is -123.09 %. In the previous year, Net Profit Margin was -343.40 % — a change of -64.16% (higher).

Net Margin

-123.09 %

YoY

-64.16%

Last updated:

Net Profit Margin of PRISM BioLab Co is 2025 -123.09 % . Net Profit Margin of PRISM BioLab Co was 2024 -343.40 % . It decreases by -64.16% higher compared to the previous year.

For PRISM BioLab Co, the net margin of -123.2% is down versus 13.2% a few years ago.

The PRISM BioLab Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2022
13.16 JPY
Jan 1, 2023
-466.60 JPY
Jan 1, 2024
-343.40 JPY
Jan 1, 2025
-123.09 JPY
The PRISM BioLab Co Net Margin history
YEARNet MarginYoY
-123.09 %-64.16%
-343.40 %-26.40%
-466.60 %-3,645.43%
13.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

Net Profit Margin of PRISM BioLab Co is -123.09 % in 2025.

Net Profit Margin of PRISM BioLab Co changed from -343.40 % to -123.09 %, representing a -64.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's PRISM BioLab Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co